Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

VTB shareholders to discuss an additional issue of shares on April 25

3/21/23 VTBR

Rosbank's profit according to IFRS in 2022 decreased 4 times

3/21/23 ROSB

Rostelecom has formed a cluster for consumer services

3/21/23 RTKM

NKHP reported for 2022 according to IFRS

3/21/23 NKHP

Cherkizovo may build a sunflower processing plant in the Penza region

3/21/23 GCHE

Bank of Russia banned the admission to trading of securities with unfriendly infrastructure

3/21/23 SPBE

Yuzhuralnickel reported for 2022 according to RAS

3/21/23 UNKL

KazanExpress will build an industrial park with a village for marketplace sellers

3/21/23 VKCO

VTB to reconvene shareholders to decide on capital increase

3/21/23 VTBR

Rosneft started test development of the Payakhskoye field

3/21/23 ROSN